| Abstract: | ![]()
Recently much interest has been shown in the antipsychotic efficacy of neuroleptic-like neuropeptides in schizophenia. In this article the clinical effects of the non-opioid fragments of γ-endorphin, the so-called γ-type endorphins DTγE and DEγE, are reviewed. In addition, preliminary clinical studies of peptides related to cholecystokinin are considered. It is concluded that γ-type endorphins possess antipsychotic properties in a subgroup of patients who may belong to Type I schizophrenia. With cholecystokinin-related peptides, in particular ceruletide, antipsychotic effects have been reported which seem to be more or less comparable to those observed with γ-type endorphins. |
